The renin-angiotensin-aldosterone system in peritoneal dialysis: Is what is good for the kidney also good for the peritoneum

Kidney International

Volumn 78, Issue 1, 2010, Pages 23-28

  Nessim, Sharon J ^a   Perl, Jeffrey ^b   Bargman, Joanne M ^c  

^a MCGILL UNIVERSITY   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Angiotensin; Fibrosis; Neoangiogenesis; Peritoneal dialysis; Peritoneal membrane; Renin

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; DIALYSIS FLUID; GLUCOSE;

GLUCOSE METABOLISM; HUMAN; MESENCHYME CELL; MESOTHELIUM CELL; NONHUMAN; PERITONEAL DIALYSIS; PERITONEUM; PH; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SHORT SURVEY; BIOSYNTHESIS; CHEMICALLY INDUCED; CYTOLOGY; EPITHELIUM; EPITHELIUM CELL; FIBROSIS; INFLAMMATION; KIDNEY; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; ULTRAFILTRATION; VASCULARIZATION;

DIALYSIS SOLUTIONS; EPITHELIAL CELLS; EPITHELIUM; FIBROSIS; GLUCOSE; HUMANS; INFLAMMATION; KIDNEY; NEOVASCULARIZATION, PATHOLOGIC; PERITONEAL DIALYSIS; PERITONEUM; RENIN-ANGIOTENSIN SYSTEM; TRANSFORMING GROWTH FACTOR BETA; ULTRAFILTRATION;

EID: 77953687629     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.90     Document Type: Short Survey

References (52)

1. Garosi G, Di Paolo N, Sacchi G et al. Sclerosing peritonitis: a nosological entity. Perit Dial Int 2005; 25(Suppl 3): S110-S112.
2. Plum J, Hermann S, Fussholler A et al. Peritoneal sclerosis in peritoneal dialysis patients related to dialysis settings and peritoneal transport properties. Kidney Int Suppl 2001; 78: S42-S47.
3. Contreras-Velazquez JC, Soto V, Jaramillo-Rodriguez Y et al. Clinical outcomes and peritoneal histology in patients starting peritoneal dialysis are related to diabetic status and serum albumin levels. Kidney Int Suppl 2008: 108: S34-S41.
4. Bertoli SV, Buzzi L, Ciurlino D et al. Morpho-functional study of peritoneum in peritoneal dialysis patients. J Nephrol 2003; 16: 373-378.
5. Williams JD, Craig KJ, Topley N et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13: 470-479.
6. Williams JD, Craig KJ, Topley N et al. Peritoneal dialysis: changes to the structure of the peritoneal membrane and potential for biocompatible solutions. Kidney Int Suppl 2003: 84: S158-S161.
7. Rubin J, Herrera GA, Collins D. An autopsy study of the peritoneal cavity from patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1991; 18: 97-102.
8. Krediet RT, Zweers MM, van der Wal AC et al. Neoangiogenesis in the peritoneal membrane. Perit Dial Int 2000; 20(Suppl 2): S19-S25.
9. Mateijsen MA, van der Wal AC, Hendriks PM et al. Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis. Perit Dial Int 1999; 19: 517-525.
10. Davies SJ. Longitudinal relationship between solute transport and ultrafiltration capacity in peritoneal dialysis patients. Kidney Int 2004; 66: 2437-2445.
11. Kawaguchi Y, Hasegawa T, Nakayama M et al. Issues affecting the longevity of the continuous peritoneal dialysis therapy. Kidney Int Suppl 1997; 62: S105-S107.
12. Smit W, Schouten N, van den Berg N et al. Analysis of the prevalence and causes of ultrafiltration failure during long-term peritoneal dialysis: a cross-sectional study. Perit Dial Int 2004; 24: 562-570.
13. Gilbert RE, Wu LL, Kelly DJ et al. Pathological expression of renin and angiotensin II in the renal tubule after subtotal nephrectomy. Implications for the pathogenesis of tubulointerstitial fibrosis. Am J Pathol 1999; 155: 429-440.
14. Wu LL, Cox A, Roe CJ et al. Transforming growth factor beta 1 and renal injury following subtotal nephrectomy in the rat: role of the renin-angiotensin system. Kidney Int 1997; 51: 1553-1567.
15. Gilbert RE, Cox A, Wu LL et al. Expression of transforming growth factor-beta1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of ACE inhibition. Diabetes 1998; 47: 414-422.
16. Ma LJ, Yang H, Gaspert A et al. Transforming growth factor-beta-dependent and-independent pathways of induction of tubulointerstitial fibrosis in beta6(-/-) mice. Am J Pathol 2003; 163: 1261-1273.
17. Noh H, Ha H, Yu MR et al. Angiotensin II mediates high glucose-induced TGF-beta1 and fibronectin upregulation in HPMC through reactive oxygen species. Perit Dial Int 2005; 25: 38-47.
18. Kiribayashi K, Masaki T, Naito T et al. Angiotensin II induces fibronectin expression in human peritoneal mesothelial cells via ERK1/2 and p38 MAPK. Kidney Int 2005; 67: 1126-1135.
19. Gilbert RE, Krum H, Wilkinson-Berka J et al. The renin-angiotensin system and the long-term complications of diabetes: pathophysiological and therapeutic considerations. Diabet Med 2003; 20: 607-621.
20. Schroppel B, Fischereder M, Wiese P et al. Expression of glucose transporters in human peritoneal mesothelial cells. Kidney Int 1998; 53: 1278-1287.
21. Ha H, Cha MK, Choi HN et al. Effects of peritoneal dialysis solutions on the secretion of growth factors and extracellular matrix proteins by human peritoneal mesothelial cells. Perit Dial Int 2002; 22: 171-177.
22. Ha H, Yu MR, Lee HB. High glucose-induced PKC activation mediates TGF-beta 1 and fibronectin synthesis by peritoneal mesothelial cells. Kidney Int 2001; 59: 463-470.
23. Morgera S, Schlenstedt J, Giessing M et al. Glucose-mediated transforming growth factor-beta1 release in human mesothelial cells is endothelin independent. J Cardiovasc Pharmacol 2004; 44(Suppl 1): S216-S218.
24. Nakamoto H, Imai H, Fukushima R et al. Role of the renin-angiotensin system in the pathogenesis of peritoneal fibrosis. Perit Dial Int 2008; 28(Suppl 3): S83-S87.
25. Mortier S, Faict D, Lameire NH et al. Benefits of switching from a conventional to a low-GDP bicarbonate/lactate-buffered dialysis solution in a rat model. Kidney Int 2005; 67: 1559-1565.
26. Ersoy R, Celik A, Yilmaz O et al. The effects of irbesartan and spironolactone in prevention of peritoneal fibrosis in rats. Perit Dial Int 2007; 27: 424-431.
27. Margetts PJ, Kolb M, Galt T et al. Gene transfer of transforming growth factor-beta1 to the rat peritoneum: effects on membrane function. J Am Soc Nephrol 2001; 12: 2029-2039.
28. Margetts PJ, Gyorffy S, Kolb M et al. Antiangiogenic and antifibrotic gene therapy in a chronic infusion model of peritoneal dialysis in rats. J Am Soc Nephrol 2002; 13: 721-728.
29. Yanez-Mo M, Lara-Pezzi E, Selgas R et al. Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells. N Engl J Med 2003; 348: 403-413. (Pubitemid 36159357)
30. Margetts PJ, Bonniaud P, Liu L et al. Transient overexpression of TGF-{beta}1 induces epithelial mesenchymal transition in the rodent peritoneum. J Am Soc Nephrol 2005; 16: 425-436.
31. Aroeira LS, Aguilera A, Sanchez-Tomero JA et al. Epithelial to mesenchymal transition and peritoneal membrane failure in peritoneal dialysis patients: pathologic significance and potential therapeutic interventions. J Am Soc Nephrol 2007; 18: 2004-2013.
32. Carvajal G, Rodriguez-Vita J, Rodrigues-Diez R et al. Angiotensin II activates the Smad pathway during epithelial mesenchymal transdifferentiation. Kidney Int 2008; 74: 585-595.
33. Sauter M, Cohen CD, Wornle M et al. ACE inhibitor and AT1-receptor blocker attenuate the production of VEGF in mesothelial cells. Perit Dial Int 2007; 27: 167-172.
34. Duman S, Gunal AI, Sen S et al. Does enalapril prevent peritoneal fibrosis induced by hypertonic (3.86%) peritoneal dialysis solution? Perit Dial Int 2001; 21: 219-224.
35. Duman S, Sen S, Duman C et al. Effect of valsartan versus lisinopril on peritoneal sclerosis in rats. Int J Artif Organs 2005; 28: 156-163.
36. Kolesnyk I, Dekker FW, Noordzij M et al. Impact of ACE inhibitors and AII receptor blockers on peritoneal membrane transport characteristics in long-term peritoneal dialysis patients. Perit Dial Int 2007; 27: 446-453.
37. Kolesnyk I, Noordzij M, Dekker FW et al. A positive effect of AII inhibitors on peritoneal membrane function in long-term PD patients. Nephrol Dial Transplant 2009; 24: 272-277.
38. Fang W, Oreopoulos DG, Bargman JM. Use of ACE inhibitors or angiotensin receptor blockers and survival in patients on peritoneal dialysis. Nephrol Dial Transplant 2008; 23: 3704-3710.
39. Bajo MA, Selgas R, Castro MA et al. Icodextrin effluent leads to a greater proliferation than glucose effluent of human mesothelial cells studied ex vivo. Perit Dial Int 2000; 20: 742-747.
40. Liberek T, Topley N, Mistry CD et al. Cell function and viability in glucose polymer peritoneal dialysis fluids. Perit Dial Int 1993; 13: 104-111.
41. Posthuma N, Verbrugh HA, Donker AJ et al. Peritoneal kinetics and mesothelial markers in CCPD using icodextrin for daytime dwell for two years. Perit Dial Int 2000; 20: 174-180.
42. Kim YL, Kim JH, Kim CD et al. Effects of icodextrin on advanced glycation end-product formation and peritoneal morphology in rats. J Am Soc Nephrol 1999; 10: 317A.
43. Nakao A, Nakao K, Takatori Y et al. Effects of icodextrin peritoneal dialysis solution on the peritoneal membrane in the STZ-induced diabetic rat model with partial nephrectomy. Nephrol Dial Transplant 2009 (e-pub ahead of print).
44. Davies SJ, Brown EA, Frandsen NE et al. Longitudinal membrane function in functionally anuric patients treated with APD: data from EAPOS on the effects of glucose and icodextrin prescription. Kidney Int 2005; 67: 1609-1615.
45. Kim CD, Kwon HM, Park SH et al. Effects of low glucose degradation products peritoneal dialysis fluid on the peritoneal fibrosis and vascularization in a chronic rat model. Ther Apher Dial 2007; 11: 56-64.
46. Williams JD, Topley N, Craig KJ et al. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004; 66: 408-418.
47. Kim S, Oh J, Chung W et al. Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study. Nephrol Dial Transplant 2009; 24: 2899-2908.
48. Fusshoeller A, Plail M, Grabensee B et al. Biocompatibility pattern of a bicarbonate/lactate-buffered peritoneal dialysis fluid in APD: a prospective, randomized study. Nephrol Dial Transplant 2004; 19: 2101-2106.
49. Freundlich M, Quiroz Y, Zhang Z et al. Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int 2008; 74: 1394-1402.
50. Kong J, Qiao G, Zhang Z et al. Targeted vitamin D receptor expression in juxtaglomerular cells suppresses renin expression independent of parathyroid hormone and calcium. Kidney Int 2008; 74: 1577-1581.
51. Zhang Z, Sun L, Wang Y et al. Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney Int 2008; 73: 163-171.
52. Taskapan H, Ersoy FF, Passadakis PS et al. Severe vitamin D deficiency in chronic renal failure patients on peritoneal dialysis. Clin Nephrol 2006; 66: 247-255.